Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
09:00am, Wednesday, 22'nd Apr 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a broad body of evidence supporting its Prospera test at the 2026
Merit Financial Group LLC Buys 4,610 Shares of Natera, Inc. $NTRA
06:00am, Monday, 20'th Apr 2026
Merit Financial Group LLC lifted its stake in Natera, Inc. (NASDAQ: NTRA) by 32.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC)
Natera, Inc. $NTRA Shares Sold by Mirae Asset Global Investments Co. Ltd.
05:18am, Monday, 20'th Apr 2026
Mirae Asset Global Investments Co. Ltd. reduced its stake in Natera, Inc. (NASDAQ: NTRA) by 21.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities a
Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst
02:30pm, Tuesday, 14'th Apr 2026
William Blair initiated coverage on Natera Inc. (NASDAQ:NTRA), highlighting the company's strong positioning in the emerging minimal residual disease (MRD) testing market and its broader growth outloo
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ: ALLO) interim futility analysis
Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents
06:00am, Thursday, 09'th Apr 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent decision issued by the United States District
3,949 Shares in Natera, Inc. $NTRA Acquired by Azzad Asset Management Inc. ADV
03:32am, Wednesday, 08'th Apr 2026
Azzad Asset Management Inc. ADV bought a new position in shares of Natera, Inc. (NASDAQ: NTRA) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund bought 3,94
20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform
06:00am, Tuesday, 07'th Apr 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts, including two oral presentations, featuring data
Exchange Traded Concepts LLC Sells 2,945 Shares of Natera, Inc. $NTRA
03:52am, Saturday, 04'th Apr 2026
Exchange Traded Concepts LLC lessened its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 40.4% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 4,346 sh
Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery
12:48pm, Tuesday, 31'st Mar 2026
Natera stock is showing exceptional strength. What's fueling NTRA momentum?
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
06:00am, Tuesday, 31'st Mar 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a publication in Clinical Cancer Research showing that Signatera w
3,400 Shares in Natera, Inc. $NTRA Purchased by Connective Portfolio Management LLC
04:45am, Thursday, 26'th Mar 2026
Connective Portfolio Management LLC bought a new stake in shares of Natera, Inc. (NASDAQ: NTRA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities a
Natera Looks Compelling As Oncology Testing Momentum Keeps Building
11:51am, Tuesday, 17'th Mar 2026
NTRA's oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in can
Bamco Inc. NY Trims Stock Position in Natera, Inc. $NTRA
04:08am, Tuesday, 17'th Mar 2026
Bamco Inc. NY lessened its stake in Natera, Inc. (NASDAQ: NTRA) by 53.3% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The f
NTRA Debuts Zenith Genomics Next-Gen Sequencing Test for Rare Diseases
10:42am, Monday, 16'th Mar 2026
Natera launches Zenith genomics whole-genome sequencing assay with MyOme to boost rare disease detection and expand diagnostics reach across the United States.
